There is a large space for domestic substitution of pharmaceutical equipment, and pharmaceutical companies have rushed to the market!

【Pharmaceutical Network Market Analysis】After Chunguang Pharmaceutical Packaging was listed on the Beijing Stock Exchange on December 16, another pharmaceutical equipment company plans to go public! Chuangzhi Technology (Jiangsu) Co.
, Ltd.
updated the listing application review on December 12, because the issuer has completed the update of financial information, according to relevant regulations, the Shenzhen Stock Exchange resumed its listing review
.
There is a large space for domestic substitution of pharmaceutical equipment, and pharmaceutical companies have rushed to the market! (Image source: Pharmaceutical Network) Another pharmaceutical machine company to be listed Chuangzhi Technology is committed to providing pharmaceutical companies with a full set of customized intelligent solutions
in the field of pharmaceutical solid dosage forms.
According to the prospectus disclosed by the company, the company intends to rush to IPO listing on the Growth Enterprise Market of the Shenzhen Stock Exchange, and the company intends to issue no more than 29,568,000 shares in its initial public offering (excluding the number of shares issued using the over-allotment option), and the new shares issued by the public account for no less than 25%
of the total share capital after this offering.
Chuangzhi Technology plans to invest 550 million yuan this time, and the funds raised will be used for high-end pharmaceutical equipment industrialization construction projects, R&D center construction projects, and supplementary working capital
.
Financial data shows that the company's performance has grown
steadily in recent years.
From January to June 2019, 2020, 2021 and 2022, the operating income realized was 120 million yuan, 126 million yuan, 209 million yuan and 128 million yuan, respectively; During the same period, the net profit attributable to the shareholders of the parent company was 45.
6416 million yuan, 33.
822 million yuan, 62.
8396 million yuan and 35.
1869 million yuan
respectively.
In addition, during the reporting period, the gross profit margins of the company's main business were 60.
98%, 58.
46%, 57.
31% and 51.
24%, respectively, which were at a high level
overall.
Behind the road of pharmaceutical machinery companies rushing to listing, it can be seen that enterprises are optimistic about the development opportunities of China's pharmaceutical equipment industry, as well as the ambition to accelerate the company's growth, expand business scale, and enhance the market competitiveness of enterprises
.
In recent years, with the rapid development of the pharmaceutical industry, and the new medical reform such as centralized procurement has forced domestic pharmaceutical companies to transform into innovative drugs, more and more pharmaceutical companies have accelerated commercialization, and CDMO companies have also ushered in a new round of opportunities, which has significantly increased the fixed asset investment of the domestic pharmaceutical manufacturing industry and driven the growth
of the pharmaceutical equipment market.
According to industry estimates, the market size of China's pharmaceutical equipment industry in 2021 will be 80.
6 billion yuan, of which the revenue of domestic pharmaceutical equipment enterprises will be between
65 billion and 70 billion yuan.
In the future, with the rapid development of biological pharmaceutical industries such as vaccines and monoclonal antibodies, it is expected that the upstream equipment field of these industries will have room for domestic substitution
.
At present, intelligence, digitalization, integration, etc.
have become the development trend of the pharmaceutical equipment industry, and at the same time, pharmaceutical machinery companies are gradually transforming from a single equipment supplier to an overall solution provider.

From the perspective of the above two pharmaceutical machine companies, the funds raised by their listing are used for the construction of intelligent automation equipment production bases, which shows the determination
of the intelligent transformation of the two pharmaceutical machine companies.
At present, the concentration of the domestic pharmaceutical equipment industry is not high, in addition to Chutian Technology, Dongfulong and other head enterprises, the rest are mostly small and medium-sized enterprises, the entire market has the characteristics of small, scattered and chaotic, with some enterprises to make intelligent efforts, the future industry concentration will be improved
.
Some powerful pharmaceutical companies are also accelerating their international layout and opening up growth points
by expanding overseas markets.
For example, according to the plan of Chutian Technology, overseas sales in 2023 will increase by 30%-50% on the basis of this year, and it is expected that the company will achieve overseas business income accounting for about 50% of total revenue around 2025, and strive to strive for overseas business income to exceed domestic business income
around 2030.
Dongfulong also released the record of investor relations activities released in September this year, revealing the company's determination to layout the international market, saying: "At present, the company's product line has reached full regional coverage, and the international product line is becoming increasingly rich, so the growth ratio of the company's international revenue will gradually increase
in the future.
" However, while seeing the opportunities, it is also necessary to see that the domestic pharmaceutical equipment industry still faces many challenges
.
Some analysts of securities institutions pointed out that in recent years, domestic brand pharmaceutical equipment has risen rapidly, and most of the subdivisions have broken the monopoly of foreign capital, but there are still breakthroughs
in subdivisions such as high-end analytical instruments, some high-end reagents, and specific membrane materials.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.